What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?

Published:2020-01-29 Issue:3 Volume:13 Page:213-222
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Harrington Patrick¹²,Radia Deepti¹,de Lavallade Hugues²³

Affiliation:

1. Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, Great Maze Pond, London, UK

2. Department of Haematological Medicine, King’s College London School of Medicine, London, UK

3. Department of Haematological Medicine, King’s College Hospital NHS Foundation Trust, Denmark Hill, London, UK

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2020.1717944

Reference66 articles.

1. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

2. Moving treatment-free remission into mainstream clinical practice in CML

3. The concept of treatment-free remission in chronic myeloid leukemia

4. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

5. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia;Biomolecules;2024-05-30

2. Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype;British Journal of Haematology;2022-07-08

3. Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies;Cells;2022-05-31

4. Novel developments in chronic myeloid leukaemia;Current Opinion in Hematology;2021-01-13

5. Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?;Journal of the National Comprehensive Cancer Network;2020-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3